Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 53

Sort by

Sort Order Select

Journal Articles

Curing Ph + ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant

Adele K. Fielding

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 24–29.

https://doi.org/10.1182/hematology.2019000010

Published: 2019

Journal Articles

Meeting the needs of CML patients in resource-poor countries

Hemant Malhotra, Jerald Radich, Pat Garcia-Gonzalez

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 433–442.

https://doi.org/10.1182/hematology.2019000050

Published: 2019

Journal Articles

Novel therapies for relapsed/refractory aggressive lymphomas

Jonathon B. Cohen

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 75–82.

https://doi.org/10.1182/asheducation-2018.1.75

Published: 2018

Journal Articles

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Naranie Shanmuganathan, Timothy P. Hughes

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 168–176.

https://doi.org/10.1182/asheducation-2018.1.168

Published: 2018

Journal Articles

We do still transplant CML, don’t we?

Charles F. Craddock

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 177–184.

https://doi.org/10.1182/asheducation-2018.1.177

Published: 2018

Journal Articles

Genetics and prognosis of ALL in children vs adults

Kathryn G. Roberts

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 137–145.

https://doi.org/10.1182/asheducation-2018.1.137

Published: 2018

Journal Articles

The argument for using imatinib in CML

Simone Claudiani, Jane F. Apperley

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 161–167.

https://doi.org/10.1182/asheducation-2018.1.161

Published: 2018

Journal Articles

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine

Amy Klion

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 326–331.

https://doi.org/10.1182/asheducation-2018.1.326

Published: 2018

Journal Articles

Treatment-free remission in CML: who, how, and why?

Francois-Xavier Mahon

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 102–109.

https://doi.org/10.1182/asheducation.V2017.1.102.00014

Published: 2017

Journal Articles

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation

Robert J. Soiffer, Yi-Bin Chen

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 699–707.

https://doi.org/10.1182/asheducation-2017.1.699

Published: 2017

Journal Articles

Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation

Farhad Ravandi

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 22–27.

https://doi.org/10.1182/asheducation-2017.1.22

Published: 2017

Journal Articles

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy

Mary C. Barber, Michael J. Mauro, Javid Moslehi

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 110–114.

https://doi.org/10.1182/asheducation-2017.1.110

Published: 2017

Journal Articles

Novel approaches to therapy in CML

Ravi Bhatia

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 115–120.

https://doi.org/10.1182/asheducation-2017.1.115

Published: 2017

Journal Articles

Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Lewis B. Silverman

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 259–264.

https://doi.org/10.1182/asheducation-2017.1.259

Published: 2017

Journal Articles

Treatment of older patients with acute lymphoblastic leukemia

Nicola Gökbuget

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 573–579.

https://doi.org/10.1182/asheducation-2016.1.573

Published: 2016

Journal Articles

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Fabio Efficace, Laura Cannella

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 170–179.

https://doi.org/10.1182/asheducation-2016.1.170

Published: 2016

Journal Articles

Molecular monitoring in chronic myeloid leukemia—how low can you go?

Susan Branford

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 156–163.

https://doi.org/10.1182/asheducation-2016.1.156

Published: 2016

Journal Articles

Chronic myeloid leukemia: sequencing of TKI therapies

Jorge Cortes, Hagop Kantarjian

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 164–169.

https://doi.org/10.1182/asheducation-2016.1.164

Published: 2016

Journal Articles

Ph-like acute lymphoblastic leukemia

Thai Hoa Tran, Mignon L. Loh

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 561–566.

https://doi.org/10.1182/asheducation-2016.1.561

Published: 2016

Journal Articles

Management of adult Ph-positive acute lymphoblastic leukemia

Sabina Chiaretti, Robin Foà

Hematology Am Soc Hematol Educ Program (2015) 2015 (1): 406–413.

https://doi.org/10.1182/asheducation-2015.1.406

Published: 2015

NARROW

Curing Ph + ALL: assessing the relative contributions of chemotherapy, TKIs, and allogeneic stem cell transplant

Meeting the needs of CML patients in resource-poor countries

Novel therapies for relapsed/refractory aggressive lymphomas

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

We do still transplant CML, don’t we?

Genetics and prognosis of ALL in children vs adults

The argument for using imatinib in CML

Hypereosinophilic syndrome: approach to treatment in the era of precision medicine

Treatment-free remission in CML: who, how, and why?

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation

Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation

Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy

Novel approaches to therapy in CML

Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia

Treatment of older patients with acute lymphoblastic leukemia

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors

Molecular monitoring in chronic myeloid leukemia—how low can you go?

Chronic myeloid leukemia: sequencing of TKI therapies

Ph-like acute lymphoblastic leukemia

Management of adult Ph-positive acute lymphoblastic leukemia

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only